MabSpace and Ambrx to Collaborate on Antibody Drug Conjugates

MabSpace Biosciences of Suzhou will collaborate with San Diego's Ambrx to discover and develop multiple novel antibody drug conjugates for oncology. Both companies are known for their drug discovery platforms. Two years ago, Ambrx was bought for an undisclosed sum by two active China life science companies, Fosun Pharma and WuXi Apptec. MabSpace has developed an immune tolerance breaking technology, and Ambrx claims small-molecule-like specificity for its ADCs. Both companies have partnered drug candidates with outside pharmas. The two companies will develop the molecules jointly, sharing the cost and rights of the resulting ADC products. More details.... Share this with colleagues: // //